Juno Pharmaceuticals Pty Ltd v Millennium Pharmaceuticals, Inc

Juno Pharmaceuticals Pty Ltd sought leave to withdraw certain admissions made in its defence to cross-claims brought by Millennium Pharmaceuticals, Inc. The dispute involves patent validity and infringement concerning pharmaceutical products. The Federal Court of Australia was tasked with determining whether Juno could withdraw the admissions based on an expert opinion. The primary legal issues included whether Juno had established that the admissions were incorrect, whether the applicant had acted transparently, and the potential impact on the case and trial proceedings if the admissions were withdrawn.

The court considered the principles relevant to granting leave to withdraw an admission, focusing on the strength of Juno's case, the potential delay in the proceedings, and the transparency of Juno's actions. The court found that Juno had not yet conducted an experiment that could clarify the correctness of the admissions and had not acted transparently in delaying the application. Additionally, the court highlighted the importance of case management and the potential disruption to the trial date if the admissions were withdrawn. The expert opinion provided by Juno was deemed insufficient to warrant withdrawal of the admissions.

The Federal Court dismissed Juno's application for leave to withdraw the admissions. The reasoning underscored the need for a robust case demonstrating the incorrectness of the admissions, transparency in the proceedings, and consideration of the overall impact on the trial. The court emphasised the importance of adhering to case management principles and the potential disruption to the trial date.

The final orders of the court were that Juno's interlocutory application dated 5 March 2019 be dismissed.